SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
OCGN

Ocugen, Inc. (OCGN)

NASDAQ: OCGN · USD
Healthcare · Biotechnology
$0.77+$0.04 (+4.79%)
 
Market cap
$261M
Insider Score
Analyst consensus
Website
Market Cap$260.55M-30.8%
Revenue (ttm)$4.78M
Net Income-$65.36M
EPS-$0.20
Shares Out339.31M
PE Ration/a
Forward PE-4.27
Dividendn/a
Ex-Dividend Daten/a
Volume6,186,721
Open$0.71
Previous Close$0.73
Day's Range$0.71 - $0.82
52-Week Range$0.69 - $2.73
Beta1.98
AnalystsStrong Buy
Price Target$12.17(+1484.41%)
Earnings DateNov 4, 2026

About OCGN

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Address
11 Great Valley Parkway, Malvern, PA, 19355, United States
Market Cap
261 million
Employees
116
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$1.09M
Bought
$25.83K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 Sell

1 firm rating OCGN in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
+4.77%
5 Days
-7.25%
1 Month
-2.78%
6 Months
-42.69%
1 Year
-30.81%

$OCGN stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in OCGN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by OCGN's directors and management

Net Shares Purchased by Insiders−600k−300k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

OCGN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

OCGN Revenue by Segment

$19.65MTotal
Change in fair value of derivative liability$16.56M84.27%
Collaborative Arrangements$1.95M9.93%
Facilities and other support costs$837.00K4.26%
Other$303.00K1.54%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New OCGN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to OCGN from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from OCGN’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
0
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
1
Sells
4
Buy Value
$25.83K
Distinct Buyers
1

Insider Score Trend Over Time

+0.0 since Sep 12
0255075100Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 26.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 12Sep 23Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

MOONDirexion Moonshot Innovators ETF2.12%
GERMETFMG Treatments, Testing and Advancements ETF0.76%
IDNAiShares Genomics Immunology and Healthcare ETF0.28%
XDNA.TOiShares Genomics Immunology and Healthcare Index ETF CAD0.24%
XBIState Street SPDR S&P Biotech ETF0.10%
IWCiShares Micro-Cap ETF0.08%
KOMPState Street SPDR S&P Kensho New Economies Composite ETF0.07%
PWSPacer WealthShield ETF0.02%
LABUDirexion Daily S&P Biotech Bull 3X Shares0.02%
VHTVanguard Health Care ETF0.00%

Weight is the stock’s share of each fund’s holdings.